​

CG Oncology Stock (NASDAQ:CGON)

ForecastRevenueOwnershipFinancialsChart
CG Oncology by TradingView

Previous Close

$33.63

52W Range

$14.80 - $40.47

50D Avg

$27.07

200D Avg

$27.06

Market Cap

$2.53B

Avg Vol (3M)

$882.78K

Beta

0.88

Div Yield

-

CGON Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

113

IPO Date

-

Website

CGON Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceJun 25Mar 25
Operating Segments$52.00K$52.00K

Fiscal year ends in Dec 24 | Currency in USD

CGON Financial Summary

Dec 24Dec 23Dec 22
Revenue-$204.00K$191.00K
Operating Income$-114.67M$-55.45M$-35.25M
Net Income$-88.04M$-48.61M$-35.44M
EBITDA$-114.67M$-55.43M$-35.23M
Basic EPS$-1.41$-15.65$-0.53
Diluted EPS$-1.41$-15.65$-0.53

Fiscal year ends in Dec 24 | Currency in USD